多发性硬化症的对症治疗：大麻素在治疗痉挛中的作用。
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.
机构信息
Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
出版信息
Ther Adv Neurol Disord. 2012 Sep;5(5):255-66. doi: 10.1177/1756285612453972.
Abstract
A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with MS. Based on these data, nabiximols (Sativex), a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, received approval for treating MS-related spasticity in various countries around the globe. In this article we review the current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option addressing spasticity in patients with MS.
摘要
很大一部分多发性硬化症（MS）患者都有痉挛，这对他们的生活质量有显著影响。有传闻证据表明大麻对痉挛和疼痛有有益的作用。最近，随机、双盲、安慰剂对照的研究证实了大麻素治疗 MS 患者痉挛的临床疗效。基于这些数据，从克隆的大麻属植物化学变种中提取的Δ-9-四氢大麻酚和大麻二酚 1:1 混合物纳比西莫司（Sativex）已在全球多个国家获得批准，用于治疗与 MS 相关的痉挛。本文综述了当前对大麻素生物学的理解，以及大麻素作为一种对症治疗选择在治疗 MS 患者痉挛方面的价值。
相似文献
1
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.多发性硬化症的对症治疗：大麻素在治疗痉挛中的作用。
Ther Adv Neurol Disord. 2012 Sep;5(5):255-66. doi: 10.1177/1756285612453972.
2
[Cannabinoids for symptomatic therapy of multiple sclerosis].[大麻素用于多发性硬化症的症状性治疗]
Nervenarzt. 2012 Jun;83(6):695-704. doi: 10.1007/s00115-011-3401-9.
3
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.欣百达（®）（四氢大麻酚+大麻二酚），一种内源性大麻素系统调节剂：基本特征和主要临床数据。
Expert Rev Neurother. 2011 Apr;11(4 Suppl):15-9. doi: 10.1586/ern.11.27.
4
Cannabinoids for Treatment of MS Symptoms: State of the Evidence.大麻素治疗多发性硬化症症状：证据现状。
Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x.
5
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.欣百达（盐酸度洛西汀肠溶胶囊）与氟西汀治疗抑郁症的对照研究
Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11.
6
A Critical Review of the Role of the Cannabinoid Compounds Δ-Tetrahydrocannabinol (Δ-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.大麻素化合物 Δ-四氢大麻酚（Δ-THC）和大麻二酚（CBD）及其联合在多发性硬化症治疗中的作用的批判性评价。
Molecules. 2020 Oct 25;25(21):4930. doi: 10.3390/molecules25214930.
7
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.纳比昔醇治疗运动神经元病患者痉挛症状的安全性和有效性（CANALS）：一项多中心、双盲、随机、安慰剂对照、2 期临床试验。
Lancet Neurol. 2019 Feb;18(2):155-164. doi: 10.1016/S1474-4422(18)30406-X. Epub 2018 Dec 13.
8
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.纳布西莫尔治疗多发性硬化症所致的痉挛、疼痛和泌尿症状。
Expert Opin Biol Ther. 2012 Nov;12(11):1517-31. doi: 10.1517/14712598.2012.721765. Epub 2012 Sep 7.
9
A drug discovery case history of 'delta-9-tetrahydrocannabinol, cannabidiol'.“Δ9-四氢大麻酚、大麻二酚”的药物发现案例史
Expert Opin Drug Discov. 2011 Apr;6(4):437-52. doi: 10.1517/17460441.2011.560935. Epub 2011 Mar 3.
10
Trends in prescription and cost of Sativex, a cannabinoid-based medicine, in treating patients with multiple sclerosis in England.基于大麻素的药物Sativex在英国治疗多发性硬化症患者方面的处方趋势及成本情况。
J Pharm Policy Pract. 2024 May 8;17(1):2342318. doi: 10.1080/20523211.2024.2342318. eCollection 2024.
引用本文的文献
1
Digital Technologies Applied to Control the One-Step Process of Cannabis Olive Oil Preparations.应用数字技术控制大麻橄榄油制备的一步法工艺。
Pharmaceutics. 2023 Mar 8;15(3):870. doi: 10.3390/pharmaceutics15030870.
2
Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis.纳布西莫尔剂量与多发性硬化症患者尿液样本中大麻素稳态浓度的相关性。
J Clin Med. 2022 Jun 27;11(13):3717. doi: 10.3390/jcm11133717.
3
Crotalphine Attenuates Pain and Neuroinflammation Induced by Experimental Autoimmune Encephalomyelitis in Mice.Crotalphine 减轻实验性自身免疫性脑脊髓炎引起的疼痛和神经炎症。
Toxins (Basel). 2021 Nov 22;13(11):827. doi: 10.3390/toxins13110827.
4
Neuroprotective Potential of Limonene and Limonene Containing Natural Products.柠檬烯及含柠檬烯天然产物的神经保护潜力。
Molecules. 2021 Jul 27;26(15):4535. doi: 10.3390/molecules26154535.
5
Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.大麻二酚在神经和肿瘤疾病中的作用：作用分子机制的最新进展。
Int J Mol Sci. 2021 Apr 21;22(9):4294. doi: 10.3390/ijms22094294.
6
A narrative review of the ethnomedicinal usage of Cannabis sativa Linnaeus as traditional phytomedicine by folk medicine practitioners of Bangladesh.孟加拉国民间医学从业者将印度大麻作为传统植物药的民族药用情况的叙述性综述。
J Cannabis Res. 2021 Mar 19;3(1):8. doi: 10.1186/s42238-021-00063-3.
7
Phytocannabinoid-dependent mTORC1 regulation is dependent upon inositol polyphosphate multikinase activity.植物大麻素依赖性 mTORC1 调节依赖于肌醇多磷酸激酶活性。
Br J Pharmacol. 2021 Mar;178(5):1149-1163. doi: 10.1111/bph.15351. Epub 2021 Jan 18.
8
Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations.脂源对医用大麻油制剂质量特性的影响。
Molecules. 2020 Jun 30;25(13):2986. doi: 10.3390/molecules25132986.
9
Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors.医用大麻草药制剂：为处方医生编写的指南。
Medicina (Kaunas). 2020 May 15;56(5):237. doi: 10.3390/medicina56050237.
10
Cannabinoids for pediatric epilepsy? Up in smoke or real science?大麻素治疗儿童癫痫？是烟雾缭绕还是真正的科学？
Transl Pediatr. 2015 Oct;4(4):271-82. doi: 10.3978/j.issn.2224-4336.2015.10.03.
本文引用的文献
1
Cannabinoid receptors: nomenclature and pharmacological principles.大麻素受体：命名法和药理学原理。
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):4-15. doi: 10.1016/j.pnpbp.2012.02.009. Epub 2012 Feb 28.
2
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).一项安慰剂对照、平行分组、随机撤药研究，纳入了正在接受长期 Sativex®（nabiximols）治疗的多发性硬化症所致痉挛症状患者。
Mult Scler. 2012 Feb;18(2):219-28. doi: 10.1177/1352458511419700. Epub 2011 Aug 30.
3
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.多发性硬化症的对症治疗：一种临床实践中多模式方法的综述。
Ther Adv Neurol Disord. 2011 May;4(3):139-68. doi: 10.1177/1756285611403646.
4
Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.解析大麻素受体 2 (CB2) 在健康和疾病中的免疫调节复杂性。
Immunol Res. 2011 Oct;51(1):26-38. doi: 10.1007/s12026-011-8210-5.
5
Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.δ-9-四氢大麻酚和大麻二酚口腔黏膜喷雾（Sativex）的滥用潜力和精神活性作用，一种新的大麻素药物。
Expert Opin Drug Saf. 2011 Sep;10(5):675-85. doi: 10.1517/14740338.2011.575778. Epub 2011 May 4.
6
Symptomatic management in multiple sclerosis.多发性硬化的症状管理。
Neurol Clin. 2011 May;29(2):449-63. doi: 10.1016/j.ncl.2011.01.008.
7
Neuroprotective agents: cannabinoids.神经保护剂：大麻素。
Clin Immunol. 2012 Jan;142(1):57-67. doi: 10.1016/j.clim.2011.02.010. Epub 2011 Mar 21.
8
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.一项纳比西莫司（Sativex®）作为附加治疗药物，用于治疗多发性硬化症引起的难治性痉挛的随机、双盲、安慰剂对照、平行组、富集设计研究。
Eur J Neurol. 2011 Sep;18(9):1122-31. doi: 10.1111/j.1468-1331.2010.03328.x. Epub 2011 Mar 1.
9
Role of cannabinoids in the treatment of pain and (painful) spasticity.大麻素在疼痛和（疼痛性）痉挛治疗中的作用。
Drugs. 2010 Dec 24;70(18):2409-38. doi: 10.2165/11585260-000000000-00000.
10
The multiplicity of action of cannabinoids: implications for treating neurodegeneration.大麻素的多种作用：治疗神经退行性疾病的意义。
CNS Neurosci Ther. 2011 Dec;17(6):637-44. doi: 10.1111/j.1755-5949.2010.00195.x. Epub 2010 Sep 28.
Zotero 插件